EQS-News CureVac Announces Pricing of Upsized Public Offering of Common Shares

TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common shares in an underwritten public offering at a public offering price of $9.25 per share for gross proceeds of approximately $250 million. CureVac has granted the underwriters a 30-day option to purchase up to an additional 4,054,054 common shares to be sold in the offering on the same terms and conditions. All of the shares in the offering are to be sold by CureVac N.V. The offering is expected to close on or about February 10, 2023, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Securities LLC are acting as bookrunners for the offering. Van Lanschot Kempen (USA) Inc. is acting as lead manager for the offering.

The offering is being made pursuant to an automatically effective shelf registration statement on Form F-3 (including a base prospectus and a related prospectus supplement) filed with the U.S. Securities and Exchange Commission (“SEC”) on September 17, 2021. A final prospectus supplement and accompanying base prospectus relating to and describing the final terms of the offering may be obtained, when available, from SEC’s website located at www.sec.gov or from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; and SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40^th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com.